Compare Mongodb Inc (MDB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs 10X Genomics Inc — how do they compare? Mongodb Inc trades at $385.93 (market cap $29.24B), while 10X Genomics Inc trades at $80.87 (market cap $10.07B). The key difference: Mongodb Inc is far larger — about 2.9× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and 10X Genomics Inc for 91 Days on average.
| MDB | TXG | |
|---|---|---|
Market Cap | $29.24B | $10.07B |
Volume | 1,304,995 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $472.29 | $97.74 |
52-Week Low | $225.95 | $11.48 |
Typical Hold Time | 46 Days | 91 Days |
Enterprise Value | $26.86B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $385.93, up 6.31% in the last session, reflecting strong momentum. The stock is technically bullish, with the price above key moving averages, though oscillators are neutral. Fundamentally, revenue growth is robust, with sales rising from $874M in 2022 to $2.01B in 2025, but profitability remains a challenge with negative net income. Recent news highlights the CEO transition and new AI product launches, which have generated mixed market reactions.
The outlook is cautiously optimistic, driven by raised long-term revenue targets and AI-focused innovations, but risks include persistent unprofitability and executive turnover. Analyst consensus is strongly bullish with an $456.76 price target, suggesting potential upside, though high valuation multiples warrant caution.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
